uz
Feedback
🌏 Sci-WEB℠ 🚀

🌏 Sci-WEB℠ 🚀

Yopiq kanal

🌏Main Link 👉 https://t.me/+cDTd32sDpiBiYTJh 🌏Links 👉 @sciweb 🌏Admin 👉 @science_web1 🌏Bot 👉 @sciwebbot 🌏News👉 @sciweb_news 🌏Onlinestore👉 @sciweb_onlinestore Link 👉 https://telega.io/c/+cDTd32sDpiBiYTJh Buy ads 👉 https://telega.io/c/+cDTd3

Ko'proq ko'rsatish

📈 Telegram kanali 🌏 Sci-WEB℠ 🚀 analitikasi

🌏 Sci-WEB℠ 🚀 Sinxala til segmentidagi kanali faol ishtirokchi. Hozirda hamjamiyat 32 112 obunachidan iborat bo'lib, Taʼlim toifasida 5 915-o'rinni va Shri-Lanka mintaqasida 39-o'rinni egallagan.

📊 Auditoriya ko‘rsatkichlari va dinamika

невідомо sanasidan buyon loyiha tez o‘sib, 32 112 obunachiga ega bo‘ldi.

30 Iyun, 2026 dagi oxirgi ma’lumotlarga ko‘ra kanal barqaror faollikka ega. Oxirgi 30 kunda obunachilar soni -250 ga, so‘nggi 24 soatda esa -7 ga o‘zgardi va umumiy qamrov yuqori darajada qolmoqda.

  • Tasdiqlash holati: Tasdiqlanmagan
  • Jalb etish (ER): Auditoriya o‘rtacha 6.73% darajada jalb etiladi. Nashrdan keyingi dastlabki 24 soatda kontent odatda umumiy obunachilar sonining N/A% ini tashkil etuvchi reaksiyalarni to‘playdi.
  • Post qamrovi: Har bir post o‘rtacha 2 160 marta ko‘riladi; birinchi sutkada odatda 0 ta ko‘rish yig‘iladi.
  • Reaksiyalar va o‘zaro ta’sir: Auditoriya faol: har bir postga o‘rtacha 8 ta reaksiya keladi.

📝 Tavsif va kontent siyosati

Muallif resursni shaxsiy fikrni ifoda etish maydoni sifatida ta’riflaydi:
🌏Main Link 👉 https://t.me/+cDTd32sDpiBiYTJh 🌏Links 👉 @sciweb 🌏Admin 👉 @science_web1 🌏Bot 👉 @sciwebbot 🌏News👉 @sciweb_news 🌏Onlinestore👉 @sciweb_onlinestore Link 👉 https://telega.io/c/+cDTd32sDpiBiYTJh Buy ads 👉 https://telega.io/c/+c...

Yuqori yangilanish chastotasi (oxirgi ma’lumot 01 Iyul, 2026 da olingan) sababli kanal doimo dolzarb va katta qamrovli bo‘lib qoladi. Analitika auditoriya kontent bilan faol hamkorlik qilishini, uni Taʼlim toifasidagi muhim ta’sir nuqtasiga aylantirishini ko‘rsatadi.

32 112
Obunachilar
-724 soatlar
-567 kunlar
-25030 kunlar
Postlar arxiv
♦️2022 Paper Discussion 36 - 2022-06-10 ♦️Get Access | PDF

♦️2022 Paper Discussion 35 - 2022-06-08 ♦️Get Access | PDF

♦️2022 Paper Discussion 34 - 2022-05-27 ♦️Get Access | PDF

♦️2022 Paper Discussion 33 - (Part 02) - 2022-05-20 ♦️Get Access | PDF | Markings

♦️2022 Paper Discussion 33 - (Part 01) - 2022-05-20 ♦️Get Access | PDF | Markings

♦️2022 Paper Discussion 30 - 2022-05-02 ♦️Get Access | PDF | Markings

♦️2022 Paper Discussion 29 - 2022-04-22 ♦️Get Access | PDF

♦️2022 Paper Discussion 27 - 2022-04-08 ♦️Get Access | PDF

♦️2022 Paper Discussion 26 - 2022-03-25 ♦️Get Access | PDF

♦️2022 Paper Discussion 25 -2022-03-18 ♦️Get Access | PDF

♦️2022 Paper Discussion 24 Part-B -2022-03-11 ♦️Get Access | PDF

♦️2022 Paper Discussion 24 Part-A -2022-03-10 ♦️Get Access | PDF

♦️2022 Paper Discussion 23 | Part-A -2022-03-07 ♦️Get Access | PDF

2022 Paper Discussion 22 ♦️Get Access | PDF

2022 Paper Discussion 21 |part-B ♦️Get Access | PDF

2022 Paper Discussion 21 |part-A ♦️Get Access | PDF

♦️2022 Paper Discussion 20 ♦️ Get Acces |pdf

2022 Paper Discussion 19 -2022-02-03 ♦️Get Access | PDF

2022 Paper Discussion 18 -2022-01-27 ♦️Get Access | PDF

♦️2022 Paper Discussion 17 - RD ♦️Paper PDF : Get Access | PDF #2022paper